Abstract
AbstractThe aim of the study was to retrospectively compare the effectiveness of the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols and the distribution of risk groups by the two protocols after minimal residual disease (MRD) measurement as well as its impact on survival. We reviewed the medical records of 3248 patients aged 1–18 years with newly diagnosed ALL who were treated in 14 hemato-oncological centers between 2002 and 2018 in Poland. The overall survival (OS) of 1872 children with ALL treated with the ALL IC 2002 protocol was 84% after 3 years, whereas the OS of 1376 children with ALL treated with the ALL IC 2009 protocol was 87% (P < 0.001). The corresponding event-free survival rates were 82% and 84% (P = 0.006). Our study shows that the ALL IC-BFM 2009 protocol improved the results of children with ALL compared to the ALL IC-BFM 2002 protocol in Poland. This analysis confirms that MRD marrow assessment on day 15 of treatment by FCM-MRD is an important predictive factor.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Della Starza, I. et al. Minimal residual disease in acute lymphoblastic leukemia: Technical and clinical advances. Front. Oncol. 9, 726. https://doi.org/10.3389/fonc.2019.00726 (2019).
2. Einsiedel, H. G. et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin–Frankfurt–Munster Group 87. J. Clin. Oncol. 23, 7942–7950. https://doi.org/10.1200/JCO.2005.01.1031 (2005).
3. Yeoh, A. E. et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J. Clin. Oncol. 30, 2384–2392. https://doi.org/10.1200/JCO.2011.40.5936 (2012).
4. Gokbuget, N. et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120, 2032–2041. https://doi.org/10.1182/blood-2011-12-399287 (2012).
5. ALL IC-BFM 2009 A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia. Final Version of Therapy Protocol from August-14-2009. https://www.bialaczka.org/wp-content/uploads/2016/10/ALLIC_BFM_2009.pdf (2009).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献